Universe Pharmaceuticals (UPC) Accumulated Expenses (2022 - 2024)

Universe Pharmaceuticals has disclosed Accumulated Expenses across 3 years of filings, most recently posting $49.5 million for Q3 2024.

• Accumulated Expenses for Q3 2024 came in at $49.5 million, up 1724.48% year-over-year; the trailing twelve-month figure through Sep 2024 was $49.5 million (up 1724.48% YoY), and the FY2024 annual result was $49.5 million, up 1724.48% from the prior year.
• Accumulated Expenses came in at $49.5 million for Q3 2024 at Universe Pharmaceuticals, up from $2.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $49.5 million in Q3 2024 to a low of $2.5 million in Q3 2022.
• The 3-year median for Accumulated Expenses is $2.7 million (2023), against an average of $18.2 million.
• Across the five-year window, Accumulated Expenses grew 6.79% in 2023 and soared 1724.48% in 2024, its largest moves.
• Universe Pharmaceuticals' Accumulated Expenses stood at $2.5 million in 2022, then rose by 6.79% to $2.7 million in 2023, then jumped by 1724.48% to $49.5 million in 2024.
• The last three Accumulated Expenses figures came in at $49.5 million (Q3 2024), $2.7 million (Q3 2023), and $2.5 million (Q3 2022), per Business Quant data.